Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, , Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or perineum: an open label, single-arm, phase 2 study. , The Lancet, 4(2):134-140: 2013

Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. , Cancer Immunol Immunother, 61(5):629-641. : 2012

Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, DeGeest K, Yamada SD, Waggoner S, Coleman, RL, Walker JL, Mannel RS A Phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in unreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. , Gynecol Oncol, 121(2):264-68: 2011

Dimitrios Nasioudis, Benjamin B Albright, Ashley F Haggerty, Emily M Ko, Sarah H Kim, Mark A Morgan, Nawar A Latif Survival following minimally invasive radical hysterectomy for patients with cervical carcinoma and tumor size ≤2 cm , Am J Obstet Gynecol.: 2021,224(3):317-318.e2. doi

Nasioudis D, Mastroyannis SA, Latif NA, Haggerty AF, Cory L, Giuntoli II RL, Kim SH, Morgan MA, Ko EM: Impact of systematic lymphadenectomy at the time of interval debulking surgery on the survival of patients with advanced stage epithelial ovarian carcinoma following neoadjuvant chemotherapy. , (Poster) Society of Gynecologic Oncology Annual meeting *virtual. : 2021

Pierini S, Tanyi JL, Simpkins F, George E, Uribe-Herranz M, Drapkin R, Burger R, Morgan MA, Facciabene A. Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. , JCI Insight. 2020 Aug 20;5(16):e136773. doi: 10.1172/jci.insight.136773. PMID: 32814714; PMCID: PMC7455139.: 2020

Tanyi JT, Chon HS, Morgan MA, Chambers SK, Butler KA, Langstraat CL, Powell MA, Randall LM, Vahrmeijer AL, Winer IS, Wenham RM Phase 3, randomized, single-dose, open-label study to investigate the safety and efficacy of pafolacianine sodium injection (OTL38) for intraoperative imaging of folate receptor positive ovarian cancer. , ASCO Annual Meeting *virtual. : 2021

Wethington SL, Shah PD, Martin LP, Tanyi JL, Latif NA, Morgan MA, Torigian DA, Pagan C, Rodriguez D, Domchek SM, Drapkin R, Shih I-M, Smith S, Dean E, Armstrong DK, Gaillard S, Simpkins F Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer. , ASCO Annual Meeting virtual: 2021

Buckingham L, Koenig A, Ko EM, Brensinger CM, Latif N, Hummel C, Zhang X, Morgan MA, Burger RA, Giuntoli II RL. Low rate of intraperitoneal port placement in ovarian cancer patients, a population-based assessment. , Int J Gynecol Cancer.: 2019,(7):1177-1181

Morgan MA, Polan ML, Melecot HH, Debru B, Sleemi A, Husain A Experience with a low-pressure colonic pouch (Mainz II) urinary diversion for irreparable vesicovaginal fistula and bladder extrophy in East Africa. , Int Urogynecol J, 20:1163-1168: 2009